
    
      PRIMARY OBJECTIVES:

      I. To improve visualization of tumors by developing better image reconstruction and
      correction methods.

      II. To revise the positioning devices and, if necessary, scanner table to fit a wider size
      range of women.

      OUTLINE:

      Patients undergo clinical fludeoxyglucose F-18 (FDG)-PET/CT followed by prone breast PET/CT
      and/or prone breast PET/MRI with or without gadopentetate dimeglumine (DTPA).
    
  